US EditionPublished • loading... • Updated
Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
In November 2024, Boltz-1 debuted as a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes. Since that time, the Massachusetts Institute of Technology (MIT) research team has continued to push a new standard in open-source AI-based drug development. In less than 18 months, the Boltz series of models have achieved accurate binding affinity prediction (Boltz-2) and …
1 Articles
1 Articles
Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
In November 2024, Boltz-1 debuted as a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes. Since that time, the Massachusetts Institute of Technology (MIT) research team has continued to push a new standard in open-source AI-based drug development. In less than 18 months, the Boltz series of models have achieved accurate binding affinity prediction (Boltz-2) and …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
